Scholarlink

<p>The Japanese government’s recent lowering of the legal adult age to 18 may prompt reconsideration of the minimum age for donors in the Japan Marrow Donor Program. To provide foundational data for decision-makers, this retrospective study analyzed the safety of hematopoietic stem cell donation among 1999 related donors aged 18 to 24&#xa0;years, using data from the Japanese Data Center for Hematopoietic Cell Transplantation. Severe adverse events (SAEs) occurred in 1.0% of all donors, with no significant difference between those aged 18 to 19 (0.7%) and those aged 20 to 24 (1.1%) (P = 0.59). Risk factors for SAEs included ongoing asthma treatment (HR 34.6, 95% CI 2.29–524.00, P &lt; 0.01), history of asthma (HR 11.3, 95% CI 2.46–51.70, P &lt; 0.01), and female sex (HR 4.64, 95% CI 1.51–14.20, P &lt; 0.01). However, age of 18 to 19 was not a significant risk factor (HR 0.53, 95% CI 0.14–2.01, P = 0.35). These results indicate that stem cell donation safety in 18- to 19-year-old donors is comparable to that in 20- to 24-year-olds, with increased risks linked to asthma and female sex.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety of hematopoietic stem cell donation from young related donors following the lowering of the age of legal adulthood in Japan

  • 期刊论文

  • 发表日期：

    2025年5月20日

查看全文
  • Tsuneaki Hirakawa,
  • Hiromasa Yabe,
  • Masayuki Hino,
  • Noriko Doki,
  • Satoshi Yoshihara,
  • Shuichi Ota,
  • Takahiro Fukuda,
  • Hirohisa Nakamae,
  • Jun Ishikawa,
  • Yuta Hasegawa,
  • Tetsuya Nishida,
  • Noboru Asada,
  • Hidekazu Nishikii,
  • Toshiro Kawakita,
  • Masayoshi Masuko,
  • Yasuo Mori,
  • Toshihiko Ando,
  • Kazuhiko Ikeda,
  • Marie Ohbiki,
  • Yoshiko Atsuta,
  • Nobuhiro Tsukada,
  • Ryu Yanagisawa

摘要

The Japanese government’s recent lowering of the legal adult age to 18 may prompt reconsideration of the minimum age for donors in the Japan Marrow Donor Program. To provide foundational data for decision-makers, this retrospective study analyzed the safety of hematopoietic stem cell donation among 1999 related donors aged 18 to 24 years, using data from the Japanese Data Center for Hematopoietic Cell Transplantation. Severe adverse events (SAEs) occurred in 1.0% of all donors, with no significant difference between those aged 18 to 19 (0.7%) and those aged 20 to 24 (1.1%) (P = 0.59). Risk factors for SAEs included ongoing asthma treatment (HR 34.6, 95% CI 2.29–524.00, P < 0.01), history of asthma (HR 11.3, 95% CI 2.46–51.70, P < 0.01), and female sex (HR 4.64, 95% CI 1.51–14.20, P < 0.01). However, age of 18 to 19 was not a significant risk factor (HR 0.53, 95% CI 0.14–2.01, P = 0.35). These results indicate that stem cell donation safety in 18- to 19-year-old donors is comparable to that in 20- to 24-year-olds, with increased risks linked to asthma and female sex.